Tamboran Resources Corp 8-K

What Happened

• Tamboran Resources Corporation filed an 8-K on April 14, 2026, reporting several equity financings that closed or partially closed that day.
• The company completed an institutional entitlement offer of 148,308,400 CHESS Depositary Interests (CDIs) — each CDI = 1/200th of a share — underpinned by 741,542 common shares, raising A$37.1 million at A$0.25 per CDI (offered to eligible non‑U.S. securityholders; issued under Regulation S).
• Underwriters (RBC Capital Markets and Wells Fargo Securities) exercised their 30‑day option to buy 443,491 option shares; the Option Shares closed on April 14, 2026, producing additional net proceeds of $14.7 million.
• The company closed part of a registered direct institutional entitlement offering at $35.00 per share, issuing 916,412 shares on April 14, 2026; approximately 96,698 additional shares are expected to close on or about April 15, 2026. (Initial RDO proceeds ≈ $32.07M.)

Key Details

• CDIs issued: 148,308,400 CDIs = 741,542 underlying common shares; proceeds A$37.1M (A$0.25/CDI).
• Option Shares: 443,491 shares exercised and closed, net proceeds $14.7M.
• Registered direct offering: 916,412 shares closed at $35.00 each (≈ $32.07M); 96,698 shares remain expected to close ($3.38M).
• Total underlying common shares issued/closed on April 14, 2026 (confirmed): 741,542 (CDI-backed) + 443,491 (Option Shares) + 916,412 (Initial RDO) = 2,101,445 shares; additional ~96,698 shares pending.

Why It Matters

• These transactions materially increase Tamboran’s cash position in both Australian dollars and U.S. dollars, providing capital for the company’s operations or development plans.
• Issuance of CDIs and shares increases the company’s outstanding equity and will dilute existing shareholders; investors should monitor updated share counts in subsequent filings.
• The filings include legal opinions related to the share issuances; the Regulation S CDI placement was targeted to eligible non‑U.S. holders, which affects the investor base and regulatory treatment.